Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

MHRA issues alert on risks associated with domperidone

Filed May 23rd, 2012 Laurie

Health regulators in the United Kingdom have issued a safety alert on drugs containing domperidone because they carry a slight risk of serious ventricular arrhythmia and sudden cardiac death.

In the U.K., domperidone is dispensed in prescription-strength form for the treatment of nausea and vomiting, epigastric sense of fullness, upper abdominal discomfort, and regurgitation of gastric contents in adults, according to a statement from the Medicines and Healthcare products Regulatory Agency (MHRA).

A recent review of drugs containing domperidone in Europe found they carry a slight risk of these life-threatening side effects, especially in patients older than 60 or for those who take daily doses more than 30 mg. The maximum dose available in the U.K. is 80 mg. QT prolongation and ventricular arrhythmia are already known side effects of these drugs and MHRA is advising doctors to avoid prescribing these drugs to patients with a prior heart condition.

Four recent studies have been completed and reviewed by MHRA and the agency reached its conclusion to issue an alert based on their results. The studies were looking for risks of just sudden cardiac death and for both sudden cardiac death and ventricular arrhythmia.

The agency, despite the patient and their risks, recommends prescribing domperidone at the lowest effective dose.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!